Drug Information

Drug (ID: DG80007) and It's Reported Resistant Information

• Name: Serdemetan
• Synonyms: Serdemetan|881202-45-5|N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine|JNJ 26854165|JNJ-26854165|ID6YB4W3V8|DTXSID30236830|N-(2-(1H-Indol-3-yl)ethyl)-n'-(pyridin-4-yl)benzene-1,4-diamine|serdemetanum|RefChem:182499|DTXCID60159321|JNJ-26854165 (Serdemetan)|Serdemetan [INN]|JNJ26854165|MFCD16620518|1-N-[2-(1H-indol-3-yl)ethyl]-4-N-pyridin-4-ylbenzene-1,4-diamine|UNII-ID6YB4W3V8|N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE|SERDEMETAN [WHO-DD]|MLS006011022|orb1305929|SCHEMBL3012498|CHEMBL2137530|SCHEMBL29375950|EX-A267|CHEBI:231694|GLXC-90074|HMS3654A16|JNJ 26854165 (Serdemetan)|GKB20216|JNJ-26854165 (Serdemetan)?|1,4-Benzenediamine, N-[2-(1H-indol-3-yl)ethyl]-N'-4-pyridinyl-|EBC-11416|s1172|AKOS016006774|CCG-264846|CS-0166|DB12027|NCGC00263171-01|NCGC00263171-08|AC-33109|AS-56263|FI151818|HY-12025|SMR004702818|NS00071296|SW218152-2|<p>Serdemetan</p>|BRD-K65924316-001-03-1|BRD-K65924316-001-07-2|Q27280666|N1-[2-(1H-indol-3-yl)ethyl]-N4-(4-pyridyl)benzene-1,4-diamine|n1-[2-(1h-indol-3-yl)ethyl]-n4-4-pyridinyl-1,4-benzenediamine|N~1~-[2-(1H-Indol-3-yl)ethyl]-N~4~-(pyridin-4-yl)benzene-1,4-diamine
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Breast cancer [ICD-11: 2C60]; [1]
• Formula: 6
• IsoSMILES: InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
• InChI: C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
• InChIKey: CEGSUKYESLWKJP-UHFFFAOYSA-N
• PubChem CID: 11609586
• ChEBI ID: CHEBI:231694
• DrugBank ID: DB12027

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa-miR-182-5p [1]

• Resistant Disease: Breast cancer [ICD-11: 2C60.2]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: BT-20 cells; Mammary gland; Homo sapiens (Human); CVCL_0178
• In Vitro Model: BT-474 cells; Breast; Homo sapiens (Human); CVCL_0179
• In Vitro Model: BT-549 cells; Breast; Homo sapiens (Human); CVCL_1092
• In Vitro Model: CAMA-1 cells; Breast; Homo sapiens (Human); CVCL_1115
• In Vitro Model: HCC1143 cells; Breast; Homo sapiens (Human); CVCL_1245
• In Vitro Model: HCC1806 cells; Breast; Homo sapiens (Human); CVCL_1258
• In Vitro Model: HCC1937 cells; Breast; Homo sapiens (Human); CVCL_0290
• In Vitro Model: HCC1954 cells; Breast; Homo sapiens (Human); CVCL_1259
• In Vitro Model: HCC38 cells; Breast; Homo sapiens (Human); CVCL_1267
• In Vitro Model: HCC70 cells; Breast; Homo sapiens (Human); CVCL_1270
• In Vitro Model: Hs578T cells; Breast; Homo sapiens (Human); CVCL_0332
• In Vitro Model: MCF-7 cells; Breast; Homo sapiens (Human); CVCL_0031
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: MDA-MB-361 cells; Breast; Homo sapiens (Human); CVCL_0620
• In Vitro Model: MDA-MB-436 cells; Breast; Homo sapiens (Human); CVCL_0623
• In Vitro Model: MDA-MB-468 cells; Breast; Homo sapiens (Human); CVCL_0419
• In Vitro Model: SK-BR-3 cells; Pleural effusion; Homo sapiens (Human); CVCL_0033
• In Vitro Model: T47D cells; Breast; Homo sapiens (Human); CVCL_0553
• In Vitro Model: EVSA-T cells; Ascites; Homo sapiens (Human); CVCL_1207
• In Vitro Model: Sk-BR-7 cells; Breast; Homo sapiens (Human); CVCL_5218
• In Vitro Model: SUM159PT cells; Breast; Homo sapiens (Human); CVCL_5423/CVCL_5590
• In Vitro Model: SUM44PE cells; Breast; Homo sapiens (Human); CVCL_3424
• In Vitro Model: SUM52PE cells; Breast; Homo sapiens (Human); CVCL_3425
• Experiment for Molecule Alteration: Microarray analyses
• Mechanism Description: This gene is up-regulated in serdemetan-resistance cells

References

• Ref 1: Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancerMol Pathol. 2003 Oct;56(5):286-92. doi: 10.1136/mp.56.5.286.